Association of erythrocyte fatty acid compositions with the risk of pancreatic cancer: A case–control study
Lipids · 2025
DOI: 10.1002/lipd.12420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lipids, 2025. Verfasst von Yongjin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Science and Resources, International Joint Research Laboratory for Lipid Nutrition and Safety, National Engineering Rese…. Hauptthemen laut MEDLINE: Erythrocytes, Pancreatic Neoplasms, Fatty Acids. Die Arbeit nennt 47 Literaturangaben. Gefördert von: National Key Research and Development Project of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Pancreatic cancer (PC) is one of the most fatal malignancies, which has attracted scientists to investigate its etiology and pathogenesis. Nevertheless, the association between erythrocyte fatty acids and PC risk remains unclear. This study aimed to evaluate the association between levels of erythrocyte fatty acids and PC risk. The erythrocyte fatty acid compositions of 105 PC patients and 120 controls were determined by gas chromatography. Cases and controls were frequency matched by age and sex. Multivariable conditional logistic regression model and restricted cubic spline were applied to estimate the odds ratio with 95% confidence interval (OR, 95% CI) of erythrocyte fatty acids and PC risk. Our main findings indicated a significant negative association between levels of erythrocyte total monounsaturated fatty acids (MUFA) and n‐3 polyunsaturated fatty acids (n‐3 PUFA) and the risk of PC (OR T3‐T1 = 0.30 [0.14, 0.63] and OR T3‐T1 = 0.15 [0.06, 0.33], respectively). In contrast, erythrocyte n‐6 polyunsaturated fatty acids, specifically linoleic acid (LA) and arachidonic acid (AA) levels, were positively associated with PC incidence (R T1‐T3 = 4.24 [1.97, 9.46] and OR T1‐T3 = 4.53 [2.09, 10.20]). Total saturated fatty acid (SFA), especially high levels of palmitic acid (16:0), was positively associated with the risk of PC (OR T3‐T1 = 3.25 [1.53, 7.08]). Our findings suggest that levels of different types of fatty acids in erythrocytes may significantly alter PC susceptibility. Protective factors against PC include unsaturated fatty acids such as n‐3 PUFA and MUFA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Food Science and Resources, International Joint Research Laboratory for Lipid Nutrition and Safety, National Engineering Research Center for Functional Food, School of Food Science and Technology…
- Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
- Department of Research and Development, Jiahe Foods Industry Co., Ltd, Suzhou, China.
- Department of Laboratory Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
- Department of Dairy Technology and Equipment Research, National Center of Technology Innovation for Dairy, Hohhot, China.
- School of Fundamental Sciences, Massey University, Palmerston North, New Zealand.
Förderung
- National Key Research and Development Project of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Wu, G., Wang, Y., Xiao, F., Yin, H., Yu, L., Shehzad, Q., Zhang, H., Jin, Q., & Wang, X. (2025). Association of erythrocyte fatty acid compositions with the risk of pancreatic cancer: A case–control study. Lipids. https://doi.org/10.1002/lipd.12420
Vancouver
Wang Y, Wu G, Wang Y, Xiao F, Yin H, Yu L, et al. Association of erythrocyte fatty acid compositions with the risk of pancreatic cancer: A case–control study. Lipids. 2025. doi:10.1002/lipd.12420
BibTeX
@article{Wang2025,
author = {Wang, Yongjin and Wu, Gangcheng and Wang, Yandan and Xiao, Feng and Yin, Hongming and Yu, Le and Shehzad, Qayyum and Zhang, Hui and Jin, Qingzhe and Wang, Xingguo},
title = {Association of erythrocyte fatty acid compositions with the risk of pancreatic cancer: A case–control study},
journal = {Lipids},
year = {2025},
doi = {10.1002/lipd.12420}
}
EUVIMED